Hummingbird Bioscience

Recent Finacing

Series C

Recent Raise

$125M

Hummingbird Bioscience develops precision antibody therapeutics using a proprietary Rational Antibody Discovery platform and systems biology, advancing oncology and autoimmunity candidates (HMBD-001/002/009) with industry and academic partnerships.

Founded 2014

North Region, Singapore

51-100

Private

hummingbirdbioscience.com

Highlights

Focus Areas

Biotechnology

Health Care

Oncology

Therapeutics

Recent Investors

O

Financials

$150M

Total Raised

3

Funding rounds

24

Investors

Team

Upgrade to view the team

See the team members at Hummingbird Bioscience.